The Future of mRNA

One Patient,
One Batch.

Medicine is still made for the average. But we are all unique. TheraGate is the micro-scale bio-foundry that turns digital sequences into GMP mRNA.

Request Info

System Status RNA PRODUCTION IN PROGRESS

Sequence Input

AUCG AUCG AUCG...

$1.3T

Market Size 2034

90%

Cost Reduction

24h

Lead Time

8.3B

Unique Codes

A Centralized Bottleneck.

Production of life-saving assets is concentrated in the hands of the few, at an enormous cost to the many. We are changing the model.

Astronomical Cost

High overhead makes 'One Patient One Batch' impossible in current centralized pharmaceutical hubs.

Slow Speed

Months of lead time for personalized medicine is too slow. Patients need it in real-time at point-of-care.

Fragile Network

Centralized manufacturing creates sovereignty risk and single points of failure in the global supply chain. We need distributed manufacturing for a resilient future.

mRNA is the Software.
TheraGate is the Printer.

Micro-scale Bio-foundry

Our platform turns digital sequences into GMP-compliant mRNA at the patient's bedside, enabling the Economy of One.

GMP-in-a-Box

Regulatory compliance and quality control are automated. The hardware ensures every batch meets the "Golden Standard".

Compliance as a Service

We simplify regulatory hurdles by providing a pre-release certificate. Only the variable elements need to be reviewed.

Cancer Vaccines

Primary Target

Auto-Immune

Tolerance Induction

Infectious Disease

Pandemic Ready

CAR-T Cells

In-Vivo Engineering

Disrupting the Economics.

Targeting a 90% cost reduction to bridge affordability with point-of-care usability.

Target Cost Per Patient

Standard of Care $500,000

TheraGate Target $10,000

"What you design in the lab today is GMP-ready for the patient tomorrow. No tech-transfer risk."

17.1% CAGR

mRNA Therapeutics Market Growth

Academic and Research Labs

Low barrier to entry

No tech transfer risks

Open platform: Bring your own reagent

Hospitals & Point-of-Care Centers

Simplicity: No specialized mRNA experts required on-site.

Safety: The machine ensures GMP compliance and quality control automatically.

Result: Immediate access to life-saving therapies for patients.

Talent Density

Quentin Vanwalleghem

Architect & Founder

15 years of bioprocess engineering expertise, bridging the gap from R&D concept to GMP industrialization.
Former Director of Technical R&D at GSK Vaccines.
Managed €40M+ CAPEX/OPEX budgets.

"Theragate doesn't need an army. It needs a focused, expert team to execute the blueprint."

One Patient, One Batch.